Ritholtz Wealth Management Acquires 254 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ritholtz Wealth Management grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,908 shares of the medical research company’s stock after buying an additional 254 shares during the quarter. Ritholtz Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,074,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Trueblood Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $1,056,000. Great Lakes Retirement Inc. lifted its position in shares of Thermo Fisher Scientific by 2.1% during the fourth quarter. Great Lakes Retirement Inc. now owns 4,393 shares of the medical research company’s stock worth $2,332,000 after purchasing an additional 89 shares in the last quarter. Elk River Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. Elk River Wealth Management LLC now owns 10,762 shares of the medical research company’s stock worth $5,716,000 after purchasing an additional 71 shares in the last quarter. Altfest L J & Co. Inc. lifted its holdings in Thermo Fisher Scientific by 116.7% in the fourth quarter. Altfest L J & Co. Inc. now owns 1,573 shares of the medical research company’s stock valued at $835,000 after buying an additional 847 shares during the period. Finally, Cornell Pochily Investment Advisors Inc. lifted its holdings in Thermo Fisher Scientific by 2.0% in the fourth quarter. Cornell Pochily Investment Advisors Inc. now owns 6,335 shares of the medical research company’s stock valued at $3,363,000 after buying an additional 124 shares during the period. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $1.84 during midday trading on Thursday, reaching $581.21. The stock had a trading volume of 1,034,640 shares, compared to its average volume of 1,617,943. The firm has a 50 day simple moving average of $565.13 and a 200-day simple moving average of $520.22. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The firm has a market cap of $221.62 billion, a PE ratio of 37.63, a P/E/G ratio of 2.39 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. During the same quarter last year, the firm posted $5.40 EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMO. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price objective on the stock. Raymond James increased their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird reissued an “outperform” rating and set a $670.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Finally, HSBC assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 price objective for the company. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $599.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.